UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice

Clinical transplantation, 2014-02, Vol.28 (2), p.161-165

2014

Volltextzugriff (PDF)

Disease characteristics in patients with and without psoriatic arthritis treated with etanercept

Journal of the European Academy of Dermatology and Venereology, 2014-05, Vol.28 (5), p.581-589

2014

Volltextzugriff (PDF)

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

Journal of the European Academy of Dermatology and Venereology, 2015-02, Vol.29 (2), p.361-366

2015

Volltextzugriff (PDF)

Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

Journal of the European Academy of Dermatology and Venereology, 2015-08, Vol.29 (8), p.1555-1561

2015

Volltextzugriff (PDF)

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

British journal of cancer, 2006-09, Vol.95 (5), p.581-586

2006

Volltextzugriff (PDF)

The use of granulocyte colony-stimulating factors in a Canadian outpatient setting

Current oncology (Toronto), 2014-04, Vol.21 (2), p.e229-240

2014

Volltextzugriff (PDF)

A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

Current oncology (Toronto), 2019-12, Vol.26 (6), p.e748-754

2019

Volltextzugriff (PDF)

Canadian retrospective claims data analysis of Biologics switching and retention patterns in Psoriasis Patients

Value in health, 2015-05, Vol.18 (3), p.A304-A305

2015

Volltextzugriff (PDF)

Analysis of Etanercept Treatment Patterns And Reimbursement Gaps In Patients When Transitioning from Private to Public Drug Plans

Value in health, 2015-05, Vol.18 (3), p.A168-A168

2015

Volltextzugriff (PDF)

THU0143 Single-Arm Study of Etanercept (ETN) in Adult Patients with Moderate To Severe Rheumatoid Arthritis (RA) Who Failed Adalimumab (ADA) Treatment

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.233-233

2016

Volltextzugriff (PDF)

2132 Retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

European journal of cancer (1990), 2015-09, Vol.51, p.S376-S376

2015

Volltextzugriff (PDF)

COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB

Value in health, 2016-05, Vol.19 (3), p.A229-A230

2016

Volltextzugriff (PDF)

AB0389 Number of cardiovascular risk factors may be associated with higher disease activity severity. Exploratory analysis of baseline data from the canadian MTX and etanercept outcome study: a randomized trial of etanercept and MTX vs etanercept alone in RA

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.659-659

2013

Volltextzugriff (PDF)

THU0173 Achievement and Maintenance of Remission/Low Disease Activity over 24 Months in Patients with Rheumatoid Arthritis Treated with Etanercept or Etanercept + Methotrexate in the Canadian Methotrexate and Etanercept Outcome (CAMEO) Study

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.240

2014

Volltextzugriff (PDF)

Comparaison de l’augmentation de la dose et de l’intensification du traitement d’association chez les patients atteints de polyarthrite rhumatoïde qui amorcent un traitement biologique par l’étanercept, l’adalimumab et l’infliximab

Revue du rhumatisme (Ed. française : 1993), 2016-11, Vol.83, p.A187-A188

2016

Volltextzugriff (PDF)

FRI0161 Response to etanercept-methotrexate therapy and etanercept monotherapy in rheumatoid arthritis patients with moderate and severe disease in the cameo trial

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A425-A426

2013

Volltextzugriff (PDF)

Différences de gravité du psoriasis chez des sujets atteints ou non de rhumatisme psoriasique et traités par l’étanercept

Annales de dermatologie et de vénéréologie, 2012-12, Vol.139 (12), p.B283-B284

2012

Volltextzugriff (PDF)

Etanercept in the treatment of palmoplantar pustulosis

Journal of drugs in dermatology, 2008-10, Vol.7 (10), p.940

2008

Volltextzugriff (PDF)

PSY74 - Canadian retrospective claims data analysis of Biologics switching and retention patterns in Psoriasis Patients

Value in health, 2015-05, Vol.18 (3), p.A304-A305

2015

Volltextzugriff (PDF)

PMS88 - Analysis of Etanercept Treatment Patterns And Reimbursement Gaps In Patients When Transitioning from Private to Public Drug Plans

Value in health, 2015-05, Vol.18 (3), p.A168-A168

2015

Volltextzugriff (PDF)

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-01

2018

Volltextzugriff (PDF)

PMS29 - COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB

Value in health, 2016-05, Vol.19 (3), p.A229-A230

2016

Volltextzugriff (PDF)

THU0173 Achievement and Maintenance of Remission/Low Disease Activity over 24 Months in Patients with Rheumatoid Arthritis Treated with Etanercept or Etanercept + Methotrexate in the Canadian Methotrexate and Etanercept Outcome (CAMEO) Study: Table 1

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.240-240

2014

Volltextzugriff (PDF)

Etiology of community-acquired pneumonia treated in an ambulatory setting

Respiratory medicine, 2005, Vol.99 (1), p.60-65

2005

Volltextzugriff (PDF)

The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5036-5036

2007

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(35)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(12)
Life Sciences & Biomedicine
(12)
Middle Aged
(12)
Science & Technology
(12)
Adult
(11)
Female
(11)
Male
(11)
Aged
(7)
Oncology
(7)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Dermatology
(5)
Original
(5)
Antineoplastic Agents
(4)
Chemotherapy
(4)
Etanercept
(4)
Head And Neck Neoplasms - Drug Therapy
(4)
Immunoglobulin G - Therapeutic Use
(4)
Pharmacology. Drug Treatments
(4)
Psoriasis - Drug Therapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice

Disease characteristics in patients with and without psoriatic arthritis treated with etanercept

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

The use of granulocyte colony-stimulating factors in a Canadian outpatient setting

A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

Canadian retrospective claims data analysis of Biologics switching and retention patterns in Psoriasis Patients

Analysis of Etanercept Treatment Patterns And Reimbursement Gaps In Patients When Transitioning from Private to Public Drug Plans

THU0143 Single-Arm Study of Etanercept (ETN) in Adult Patients with Moderate To Severe Rheumatoid Arthritis (RA) Who Failed Adalimumab (ADA) Treatment

2132 Retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB

AB0389 Number of cardiovascular risk factors may be associated with higher disease activity severity. Exploratory analysis of baseline data from the canadian MTX and etanercept outcome study: a randomized trial of etanercept and MTX vs etanercept alone in RA

THU0173 Achievement and Maintenance of Remission/Low Disease Activity over 24 Months in Patients with Rheumatoid Arthritis Treated with Etanercept or Etanercept + Methotrexate in the Canadian Methotrexate and Etanercept Outcome (CAMEO) Study

Comparaison de l’augmentation de la dose et de l’intensification du traitement d’association chez les patients atteints de polyarthrite rhumatoïde qui amorcent un traitement biologique par l’étanercept, l’adalimumab et l’infliximab

FRI0161 Response to etanercept-methotrexate therapy and etanercept monotherapy in rheumatoid arthritis patients with moderate and severe disease in the cameo trial

Différences de gravité du psoriasis chez des sujets atteints ou non de rhumatisme psoriasique et traités par l’étanercept

Etanercept in the treatment of palmoplantar pustulosis

PSY74 - Canadian retrospective claims data analysis of Biologics switching and retention patterns in Psoriasis Patients

PMS88 - Analysis of Etanercept Treatment Patterns And Reimbursement Gaps In Patients When Transitioning from Private to Public Drug Plans

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

PMS29 - COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB

THU0173 Achievement and Maintenance of Remission/Low Disease Activity over 24 Months in Patients with Rheumatoid Arthritis Treated with Etanercept or Etanercept + Methotrexate in the Canadian Methotrexate and Etanercept Outcome (CAMEO) Study: Table 1

Etiology of community-acquired pneumonia treated in an ambulatory setting

The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)

Suchergebnisse filtern